An official website of the United States government Here's how you know

The .gov means it's official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Drugs@FDA: FDA-Approved Drugs

Home | Previous Page

New Drug Application (NDA): 050790
Company: ABBVIE

Products on NDA 050790

Drug Name	Active Ingredients	Strength	Dosage Form/Route	Marketing Status	TE Code	RLD	RS
RESTASIS	CYCLOSPORINE	0.05%	EMULSION;OPHTHALMIC	Prescription	AB	Yes	Yes
RESTASIS MULTIDOSE	CYCLOSPORINE	0.05%	EMULSION;OPHTHALMIC	Prescription	None	Yes	Yes

Approval Date(s) and History, Letters, Labels, Reviews for NDA 050790

Original Approvals or Tentative Approvals

Action Date	Submission	Action Type	Submission Classification	Review Priority; Orphan Status	Letters, Reviews, Labels, Patient Package Insert	Notes	Url
12/23/2002	ORIG-1	Approval	Type 3 - New Dosage Form	PRIORITY	Label (PDF) Letter (PDF) Review		https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/050790lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2002/050790ltr.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-023_Restasis.cfm

Supplements

Action Date	Submission	Supplement Categories or Approval Type	Letters, Reviews, Labels, Patient Package Insert	Note	Url
07/18/2017	SUPPL-27	Labeling-Package Insert	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/050790s027lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/050790Orig1s027ltr.pdf
10/27/2016	SUPPL-25	Labeling-Package Insert	Label (PDF) Review (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050790s024s025lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/50790Orig1s025.pdf
10/27/2016	SUPPL-24	Manufacturing (CMC)	Label (PDF) Review (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050790s024s025lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/50790Orig1s024.pdf
12/05/2013	SUPPL-23	Manufacturing (CMC)		Label is not available on this site.
01/16/2014	SUPPL-22	Manufacturing (CMC)		Label is not available on this site.
05/31/2013	SUPPL-21	Manufacturing (CMC)	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/050790s021lbl.pdf
12/03/2012	SUPPL-20	Labeling-Package Insert	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/050790s020lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2012/050790Orig1s020ltr.pdf
01/16/2013	SUPPL-19	Manufacturing (CMC)		Label is not available on this site.
12/27/2007	SUPPL-13	Labeling-Container/Carton Labels		Label is not available on this site.
10/01/2003	SUPPL-4	Labeling	Letter (PDF)	Label is not available on this site.	https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2003/50790scp003slr004ltr,.pdf
10/01/2003	SUPPL-3	Manufacturing (CMC)-Packaging	Letter (PDF)	Label is not available on this site.	https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2003/50790scp003slr004ltr,.pdf
09/12/2003	SUPPL-2	Manufacturing (CMC)	Review	Label is not available on this site.	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/050790_S002_RestasisTOC.cfm
09/16/2003	SUPPL-1	Labeling	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/50790slr001_restasis_lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2003/50790slr001ltr.pdf

Labels for NDA 050790

Action Date	Submission	Supplement Categories or Approval Type	Letters, Reviews, Labels, Patient Package Insert	Note	Url
07/18/2017	SUPPL-27	Labeling-Package Insert	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/050790s027lbl.pdf
10/27/2016	SUPPL-25	Labeling-Package Insert	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050790s024s025lbl.pdf
10/27/2016	SUPPL-24	Manufacturing (CMC)	Label (PDF)	This supplement type does not usually require new labeling.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050790s024s025lbl.pdf
05/31/2013	SUPPL-21	Manufacturing (CMC)	Label (PDF)	This supplement type does not usually require new labeling.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/050790s021lbl.pdf
12/03/2012	SUPPL-20	Labeling-Package Insert	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/050790s020lbl.pdf
09/16/2003	SUPPL-1	Labeling	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/50790slr001_restasis_lbl.pdf
12/23/2002	ORIG-1	Approval	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/050790lbl.pdf

Therapeutic Equivalents for NDA 050790

RESTASIS

EMULSION;OPHTHALMIC; 0.05%
TE Code = AB

Drug Name	Active Ingredients	Strength	Dosage Form/Route	Marketing Status	RLD	TE Code	Application No.	Company
CYCLOSPORINE	CYCLOSPORINE	0.05%	EMULSION;OPHTHALMIC	Prescription	No	AB	207606	APOTEX
CYCLOSPORINE	CYCLOSPORINE	0.05%	EMULSION;OPHTHALMIC	Prescription	No	AB	205894	MYLAN
CYCLOSPORINE	CYCLOSPORINE	0.05%	EMULSION;OPHTHALMIC	Prescription	No	AB	203880	TEVA PHARMS USA INC
RESTASIS	CYCLOSPORINE	0.05%	EMULSION;OPHTHALMIC	Prescription	Yes	AB	050790	ABBVIE

RESTASIS MULTIDOSE

There are no Therapeutic Equivalents.

Top